LRRFIP1 antibody is predicted to not cross-react with other LRRFIP family members. Three isoforms of LRRFIP1 are known to exist, this antibody will only recognize the two longer isoforms.
纯化方法
LRRFIP1 Antibody is affinity chromatography purified via peptide column.
免疫原
LRRFIP1 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human LRRFIP1. The immunogen is located within the last 50 amino acids of LRRFIP1.
LRRFIP1
适用: 人
WB, IF
宿主: 小鼠
Polyclonal
unconjugated
应用备注
LRRFIP1 antibody can be used for detection of LRRFIP1 by Western blot at 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
限制
仅限研究用
状态
Liquid
浓度
1 mg/mL
缓冲液
LRRFIP1 Antibody is supplied in PBS containing 0.02 % sodium azide.
储存液
Sodium azide
注意事项
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
储存条件
-20 °C,4 °C
储存方法
LRRFIP1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
抗原
LRRFIP1
(Leucine Rich Repeat (In FLII) Interacting Protein 1 (LRRFIP1))
别名
LRRFIP1
背景
LRRFIP1 Antibody: LRRFIP1, also known as GC-binding factor 2 (GCF2), is a 738 amino acid transcriptional repressor that mainly plays a cytoskeletal role. It is primarily localized in the cytoplasm and preferentially binds to GC-rich dsDNA, but will also bind directly to dsRNA as well. The RNA binding domain encompasses a lysine-rich motif. LRRFIP1 interacts with the mammalian Flightless I (Fli-I) and is a key component in the cytoskeletal regulation of platelet function. LRRFIP1 and the related protein LRRFIP2 may modulate canonical WNT signaling and mediate the IRF3-induced production of type I interferon via a beta-catenin-dependent pathway.